ST
ACHN

Spot Trading’s Achillion Pharmaceuticals ACHN Stock Holding History

Spot Trading’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,800
Closed -$47K – 3367
2016
Q3 		$47K Buy
+5,800
New +$49.3K ﹤0.01% 2637
2016
Q1 		– Sell
-57,600
Closed -$622K – 4230
2015
Q4 		$622K Sell
57,600
-191,900
-77% -$1.74M 0.01% 1765
2015
Q3 		$1.72M Buy
249,500
+173,900
+230% +$1.42M 0.02% 1187
2015
Q2 		$670K Buy
+75,600
New +$715K 0.01% 1908
2015
Q1 		– Sell
-7,000
Closed -$86K – 4501
2014
Q4 		$86K Sell
7,000
-48,300
-87% -$590K ﹤0.01% 3289
2014
Q3 		$552K Buy
55,300
+27,300
+98% +$253K ﹤0.01% 2487
2014
Q2 		$212K Buy
+28,000
New +$112K ﹤0.01% 3294
2014
Q1 		– Sell
-205,000
Closed -$680K – 4648
2013
Q4 		$680K Sell
205,000
-239,800
-54% -$696K ﹤0.01% 2254
2013
Q3 		$1.34M Buy
444,800
+443,200
+27,700% +$3.04M 0.01% 1686
2013
Q2 		$13K Buy
+1,600
New +$12.2K ﹤0.01% 3956

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Spot Trading's ACHN Position: Q4 2016 in Review

Spot Trading sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 4,836 shares — an estimated $39K sold.

Spot Trading first reported a position in ACHN in Q3 2013 and held it in 7 quarters. The position peaked at $343K in Q3 2014. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Spot Trading reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 4,836 Achillion Pharmaceuticals shares in Q4 2016, an estimated $39K.
  • Spot Trading first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Spot Trading's Achillion Pharmaceuticals position peaked at $343K in Q3 2014.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.